文献速递细胞病理与分子病理

甲状腺结节ThyroSeq阴性或低风险的长期随访结果

The negative outlook: Long-term follow up of ThyroSeq negative and low-risk nodules.
PubMed 文献 · Cancer Cytopathol · 2024-06-20

本研究为单中心回顾性队列,纳入159例患者共167个细胞学不确定(Bethesda III或IV)且ThyroSeq阴性或低风险的甲状腺结节,中位随访4.0年,切除标本中3个结节为恶性(1.8%),整个队列阴性预测值为98.2%,手术系列为89.3%,提示ThyroSeq检测阴性预测值良好,常规随访可安全监测。

要点

  • 细胞学不确定且ThyroSeq阴性或低风险的结节恶性率低(1.8%)。
  • 整个队列阴性预测值达98.2%,手术系列为89.3%。
  • 常规随访可安全监测结节是否出现恶性特征。

核心结论

  • ThyroSeq检测具有良好阴性预测值,有助于细胞学不确定结节的风险分层。
  • 常规随访可安全监测结节是否出现提示恶性的特征。

研究设计与样本

  • 单中心学术机构回顾性队列研究。
  • 纳入2012至2018年接受细针穿刺且ThyroSeq检测为阴性或低风险的细胞学不确定(Bethesda III或IV)结节,共159例患者、167个结节。

主要发现

  • 159例患者平均年龄58岁(范围7-84岁),女性占81.8%。
  • 平均随访4.0年。
  • 167个结节中3个切除后证实为恶性(1.8%)。
  • 整个队列阴性预测值为98.2%,手术系列为89.3%。

关键数值与推荐

  • 整个队列阴性预测值98.2%。
  • 手术系列阴性预测值89.3%。
  • 恶性结节比例1.8%(3/167)。

临床怎么用

  • 对细胞学不确定且ThyroSeq阴性或低风险的结节,可依据阴性预测值进行风险分层并采用常规随访监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Molecular testing of thyroid nodules is an essential tool to help risk stratify nodules with indeterminate cytology. Although ThyroSeq testing has been around for over a decade, there is a paucity of long-term follow-up data on cytologically indeterminate nodules that are determined to be molecularly negative or low-risk. The objective of this study is to assess the outcomes of nodules with indeterminate cytology (Bethesda III or IV) and negative or low-risk ThyroSeq results. METHODS: This is a single academic institution retrospective cohort study. Patients with at least one thyroid nodule sampled with fine-needle aspiration who underwent ThyroSeq testing from 2012 to 2018 and had negative or low-risk ThyroSeq results on a cytologically indeterminate sample (n = 159 patients, 167 nodules) were included in the study. Outcomes include the false-negative rate and negative predictive value of each test version, as well as follow-up length for each nodule. RESULTS: There were 159 patients with a mean age of 58 years (7-84 years) included in this study; the majority were female (81.8%). The mean follow-up was 4.0 years. Of 167 nodules, three were found to be malignant on resection (1.8%). The negative predictive value for the entire cohort was 98.2% and it was 89.3% for the surgical series. CONCLUSION: ThyroSeq testing has good negative predictive value and can help risk stratify cytologically indeterminate nodules. Routine follow-up allows for safe monitoring of nodules for features suggestive of malignancy.

来源:Cancer Cytopathol,查看原文。版权归原作者所有。

引用

  1. Perry RA, Lee MF, Jug RC, et al. The negative outlook: Long-term follow up of ThyroSeq negative and low-risk nodules. Cancer Cytopathol. 2024. PMID: 39031857. doi:10.1002/cncy.22875

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。